Assertio Therapeutics Announces Closing of Sale of NUCYNTA® Franchise to Collegium Pharmaceutical for $375.0 Million

Stock Information for Assertio Holdings Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Assertio Holdings Inc.

Sig Kirk Joins Assertio Board of Directors
Assertio to Present at LD Micro Invitational Conference in New York City
ASSERTIO ALERT: Bragar Eagel & Squire, P.C. is Investigating Assertio Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Assertio Reports Fourth Quarter and Full Year 2023 Financial Results
March 5, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against ASRT
Assertio Holdings, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before March 5, 2024 to Discuss Your Rights - ASRT
DEADLINE ALERT for ASRT: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Assertio Holdings, Inc. of Class Action Lawsuit and Upcoming Deadlines - ASRT

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.